Hyderabad-based Bharat Biotech India Ltd (BBIL) on July 3 released the results of the Phase-3 trial of Covaxin. The company claimed the vaccine had an overall efficacy of 77.8% against symptomatic Coronavirus. The trials involved approximately 25,800 volunteers around 25 hospitals across the country.
As per reports, Covaxin has higher efficiency than AstraZeneca (Covishield) vaccine’s 70.4% efficacy.
As per the company, the two-dose vaccine was also 93.4% effective against severe disease and 63% protective against asymptomatic COVID. Moreover, it was 65% protective against the Delta variant.
The company suggests that the SARS-CoV-2 vaccine may also be effective against people who do not have symptoms and may help reduce the spread of Covid-19.
Twelve per cent of those who have been vaccinated have common side effects. Less than 0.5 percent have experienced serious side effects. The vaccine was developed by Bharat Biotech in partnership with ICMR and NIV.
Ashish, nephew of the famous producer Dil Raju, is to be seen in the new…
"Sriya Reddy’s return to the silver screen in Prashanth Neel’s “Salaar: Part 1 – Ceasefire”…
Prepare for the thrilling release of "Miral," a supernatural horror drama starring Bharath and Vani…
Varun Sandesh, known for his dynamic performances, is all set to captivate audiences with the…
Kalki 2898 AD, the upcoming science fiction epic, is set to push the boundaries of…
AP CM YS Jagan interacted with the team at the political agency, I-PAC today and…